The topic of coexisting aortic stenosis (AS) and cardiac amyloidosis (CA) has become a classic of contemporary cardiology due to the spread of transcatheter aortic valve replacement (TAVR) as a treatment for AS and the wide availability of bone scintigraphy as a non-invasive diagnostic standard for transthyretin-related amyloidosis (ATTR).
Aortic stenosis, transcatheter aortic valve replacement and transthyretin cardiac amyloidosis: are we progressively unraveling the tangle?
Rapezzi C.
;Campo G.
2021
Abstract
The topic of coexisting aortic stenosis (AS) and cardiac amyloidosis (CA) has become a classic of contemporary cardiology due to the spread of transcatheter aortic valve replacement (TAVR) as a treatment for AS and the wide availability of bone scintigraphy as a non-invasive diagnostic standard for transthyretin-related amyloidosis (ATTR).File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
